INNATE PHARMA SA-SPONS ADR (IPHA) Stock Analyst Ratings
USA - NASDAQ:IPHA - US45781K2042 - ADR
2.07 USD
-0.02 (-0.96%)
2.08 USD
+0.01 (+0.48%)
ChartMill assigns a Buy % Consensus number of 74% to IPHA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 6.12. This target is 195.53% above the current price.
IPHA was analyzed by 7 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about IPHA.
In the previous month the buy percentage consensus was at a similar level.
IPHA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-29 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-29 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-09-18 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-09-18 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-04-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-24 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-15 | SVB Leerink | Maintains | Outperform |
| 2022-09-16 | Citigroup | Maintains | Buy |
| 2022-08-02 | SVB Leerink | Maintains | Outperform |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2021-09-17 | SVB Leerink | Maintains | Outperform |
| 2021-09-03 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2021-09-02 | SVB Leerink | Upgrade | Market Perform -> Outperform |
INNATE PHARMA SA-SPONS ADR / IPHA FAQ
What is the average price target for INNATE PHARMA SA-SPONS ADR (IPHA) stock?
7 analysts have analysed IPHA and the average price target is 6.12 USD. This implies a price increase of 195.53% is expected in the next year compared to the current price of 2.07.
What is the consensus rating for IPHA stock?
The consensus rating for INNATE PHARMA SA-SPONS ADR (IPHA) is 74.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for INNATE PHARMA SA-SPONS ADR stock?
The number of analysts covering INNATE PHARMA SA-SPONS ADR (IPHA) is 7.